CELLECTAR BIOSCIENCES, INC.
100 Campus Drive
Florham Park, New Jersey 07932
October 26, 2023
Via EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549-3720
Attention: Ms. Cindy Polynice
Re: Acceleration Request for Cellectar Biosciences, Inc.
Registration Statement on Form S-3 (File No. 333-274880)
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, Cellectar Biosciences, Inc. (the “Company”), hereby requests that the effective date of the Company’s Registration Statement on Form S-3, Registration Number 333-274880 (the “Registration Statement”) be accelerated so that the Company’s Registration Statement will become effective at 4:00 P.M., Eastern Time or as soon thereafter as practicable, on October 30, 2023, or at such later time as the Company or its counsel may request from the staff of the Division of Corporation Finance of the U.S. Securities and Exchange Commission.
We would appreciate it if, as soon as the Registration Statement is declared effective, you would so inform Istvan A. Hajdu of Sidley Austin LLP at (212) 839-5651 or ihajdu@sidley.com.
| Very truly yours, | |
| /s/ Chad J. Kolean | |
| Chad J. Kolean | |
| Chief Financial Officer |
| cc: | James V. Caruso |
| Asher M. Rubin | |
| Istvan A. Hajdu | |
| Kostian Ciko |
